Boston Scientific (NYSE:BSX) Rating Lowered to Neutral at JPMorgan Chase & Co.

Key Points

• JPMorgan downgraded Boston Scientific from “overweight” to “neutral” and set a $46 price target, implying about 9.3% upside from the reported share price. The overall analyst consensus remains “Moderate Buy,” with an average target of $65.30.
• Boston Scientific’s latest quarterly results modestly exceeded expectations, with adjusted EPS of $0.73 and revenue of $5.14 billion. However, the company lowered its full-year outlook and warned that fourth-quarter earnings and sales could decline amid cybersecurity disruptions and other operational challenges.
• Shares fell to $42.09, while insiders—including CEO Michael Mahoney—purchased roughly $9.4 million of stock over the prior three months. Institutional investors own approximately 89.1% of the company.

Boston Scientific (NYSE:BSX - Get Free Report) was downgraded by equities research analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating in a note issued to investors on Wednesday, Marketbeat reports. They presently have a $46.00 price objective on the medical equipment provider's stock. JPMorgan Chase & Co.'s price target would suggest a potential upside of 9.28% from the company's current price.

Several other brokerages also recently weighed in on BSX. Mizuho set a $55.00 price objective on Boston Scientific in a research report on Tuesday, October 13th. Leerink Partners dropped their price objective on Boston Scientific from $60.00 to $55.00 in a research note on Friday, October 9th. Wall Street Zen cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 2nd. Canaccord Genuity Group dropped their price objective on Boston Scientific from $70.00 to $66.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Finally, Citigroup reduced their target price on shares of Boston Scientific from $50.00 to $48.00 and set a "neutral" rating for the company in a research note on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $65.30.

Boston Scientific Stock Performance

Shares of BSX traded down $2.97 during trading hours on Wednesday, hitting $42.09. The company had a trading volume of 47,989,241 shares, compared to its average volume of 18,586,006. The business has a fifty day moving average of $45.29 and a 200-day moving average of $57.71. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm has a market cap of $61.00 billion, a price-to-earnings ratio of 17.04, a PEG ratio of 1.10 and a beta of 0.58. Boston Scientific has a 12 month low of $39.57 and a 12 month high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.01. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The business had revenue of $5.14 billion during the quarter, compared to analysts' expectations of $5.06 billion. During the same period last year, the firm posted $0.75 EPS. The firm's revenue for the quarter was up 1.4% compared to the same quarter last year. Equities analysts anticipate that Boston Scientific will post 3.21 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director David Habiger acquired 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares of the company's stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 194,522 shares of company stock valued at $9,385,210 over the last three months. 0.34% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $5,534,781,000. Primecap Management Co. CA bought a new position in shares of Boston Scientific during the second quarter valued at approximately $2,156,233,000. Jupiter Topco LLC purchased a new stake in Boston Scientific in the second quarter worth $803,357,000. Bank of America Corp DE purchased a new stake in Boston Scientific in the second quarter worth $556,026,000. Finally, Legal & General Group Plc purchased a new stake in Boston Scientific in the second quarter worth $431,890,000. Institutional investors own 89.07% of the company's stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.73, slightly above the $0.72 consensus estimate, while revenue of $5.138 billion exceeded expectations of approximately $5.06 billion. Sales increased 1.5% year over year. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Management highlighted ongoing product and pipeline developments, including enrollment in the Elite AF clinical trial and FDA clearances for StoneSmart technologies and an expanded SEISMIQ catheter offering. Recent insider activity also shows purchases rather than sales, including a sizable purchase by CEO Michael Mahoney.
• Neutral Sentiment: Needham reduced its price target from $57 to $48 but retained a “Buy” rating, implying potential upside from recent trading levels. The target cut reflects a more cautious outlook despite the firm’s continued positive stance.
• Negative Sentiment: Boston Scientific lowered its full-year 2026 outlook to adjusted EPS of $3.16-$3.18. Fourth-quarter adjusted EPS guidance of $0.77-$0.79 was also below market expectations, and management indicated that fourth-quarter reported and organic sales could decline 1%-3% year over year. Boston Scientific Cuts View Again After Cyberattack, Other Challenges
• Negative Sentiment: Profitability weakened: GAAP diluted EPS fell to $0.40 from $0.51 a year earlier, while adjusted earnings declined from $0.75 per share. Investors are also concerned that the cybersecurity attack continues to disrupt IT systems, operations and sales recovery, potentially creating further pressure on margins and near-term growth. Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.